

NEWS RELEASE

BLACKHAWK'S MINDBIO THERAPEUTICS TO DEVELOP PROPRIETARY DRUG DELIVERY TECHNOLOGY FOR PSYCHEDELIC MEDICINES

| January 4, 2022



Vancouver, British Columbia – TheNewswire – January 04, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”), is developing a proprietary technology and a new scientific method to objectively test the effectiveness and delivery of microdosing psychedelic medicines.

MindBio is currently undertaking the world's first clinical trial of its kind and the data will be used to develop new technology to assist with delivering psychedelic medicines. The technology will be developed and then tested and enhanced in MindBio's Phase 2 clinical trials. The novel technology will collect data from participants in microdosing clinical trials with the aim to determine an optimal microdose for individual patients.

In its Phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide), MindBio is microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication. MindBio's strategy of microdosing of psychedelic medicines administered using smart drug delivery technology will lead to a highly scalable method for treating mental health disorders. With preparation work underway, MindBio will conduct its Phase 2 clinical trials in early 2022 microdosing patients with major depressive disorder and in patients with late-stage cancer.

“MindBio's leadership in clinical trials of psychedelic medicines has the potential to also lead to the creation of new drug delivery technologies that would allow psychedelic medicines to be administered at scale”, says Frederick Pels, CEO of Blackhawk Growth. “Using the data from our Phase 1 clinical trials to develop and test the drug delivery technology in our Phase 2 clinical trials will help accelerate our pathway to commercialization.”

1. <https://www.beckleyfoundation.org/2018/06/13/psychedelics-promote-neural-plasticity/>
2. [https://www.cell.com/cell-reports/fulltext/S2211-1247\(18\)30755-1](https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30755-1)

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Trin Pharma, Noble Hemp, Spaced Food, NuWave Foods, Digital Mind Therapeutics and MindBio



The Company diligently posts updates through videos from the official company YouTube channel <https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A>

Please join the conversation on our Blackhawk group supporter's telegram group at <https://t.me/Blackhawkgrowthcorp> and visit us online at <https://www.blackhawkgrowth.com>.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

QUICK LINKS

[Home](#)
[About](#)
[Investors](#)
[Management](#)
[Contact](#)

INVESTMENTS

Medigen Biotechnology Corp. & TBG Biotechnology Corp.
NuWave
Spaced Food
Trip Pharma
Sac Pharma
Noble Hemp

NEWS RELEASES

January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
December 2020
November 2020
October 2020
September 2020

CONTACT

303-750 West Pender Street
Vancouver, BC
V6C 2T7
T: 403-991-7737
E: info@blackhawkgrowth.com

[June 2020](#)

[May 2020](#)

[April 2020](#)

[March 2020](#)

[February 2020](#)

[January 2020](#)

© 2022 Blackhawk Growth Corp..